Teva Pharmaceuticals Industries (NYSE: $TEVA) began marketing the authorized generic of Victoza this June, and Teva CEO Richard Francis told investors during the Q3 2024 earnings call that the company plans to launch generic Saxenda in 2025
Any company currently marketing compounded GLP-1 products should conduct an immediate review of all advertising and promotional materials (including website content, social media, and direct-to-consumer communications) to ensure that no claims imply FDA approval, equivalency with branded products, or clinical validation that does not exist
And of course, what if that simple sugar were less expensive than any GLP-1 drug
"Identification and Analysis of Counterfeit Glutathione Supplements in the Global Market." Journal of Pharmaceutical Sciences, 45(3), 267-281
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7
Starting your day with protein helps preserve muscle and manage appetite throughout the day